肝细胞癌术后复发的预测与预防策略  

Prediction and preventive strategies for recurrence after surgery for hepatocellular carcinoma

作　　者：贾户亮[1] 

机构地区：[1]复旦大学附属华山医院普外科复旦大学肿瘤转移研究所,上海200040

出　　处：《中华肝脏病杂志》2016年第5期330-334,共5页Chinese Journal of Hepatology

摘　　要：通过近20年的努力，肝癌转移复发研究取得诸多进展，主要包括：（1）发现了包括骨桥蛋白在内的一组转移复发相关分子，建立并优化了多分子转移预测模型。（2）发现肿瘤微环境免疫反应状态失衡是促进转移的重要方面，可用于预测转移复发。（3）发现并证实干扰索可预防术后复发，并且miR-26a低表达者更获益。（4）液体活检和免疫治疗的突破为HCC转移复发的预测与防治带来光明前景。但是，这些预测模型尚需多中心研究进一步验证；辅助性肝动脉化学疗法栓塞术和索拉菲尼靶向治疗的作用尚需进一步评估。Many advances have been achieved in the clinical and basic studies on metastasis and recurrence of hepatocellular carcinoma （HCC） over the past 20 years. The achievements mainly include the following aspects： （1） a group of molecules related to metastasis and recurrence including osteopontin have been identified, and multi-molecular predictive models for metastasis have been established and optimized; （2） it has been found that the imbalance of immune response in tumor microenvironment is important in promoting metastasis and can be used to predict metastasis and recurrence; （3） it has been found and confirmed that interferon can prevent postoperative recurrence, and patients with a lower miR- 26a expression level can achieve greater benefits; （4） the breakthroughs in liquid biopsy and immunotherapy bring a promising future for the prediction, prevention, and treatment of HCC metastasis and recurrence. However, these predictive models still need to be validated by multi-center studies, and the effects of adjuvant transarterial chemoembolization and targeted therapy with sorafenib still need further evaluation.

关 键 词：癌 肝细胞 复发 预测 预防 

分 类 号：R735.7[医药卫生—肿瘤]